Anastasia Ivanova

List of Publications by Year in descending order

86 papers	2,036 citations	304743 22 h-index	265206 42 g-index
92 all docs	92 docs citations	92 times ranked	1474 citing authors

#	Article	IF	Citations
1	The properties of entropy as a measure of randomness in a clinical trial. Journal of Statistical Planning and Inference, 2022, 216, 182-193.	0.6	2
2	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	2.9	24
3	A phase I evaluation of the effect of curcumin on doseâ€limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors. Clinical and Translational Science, 2022, 15, 1304-1315.	3.1	12
4	Consistency of the CRM when the doseâ€toxicity curve is not monotone and its application to the POCRM. Statistics in Medicine, 2021, 40, 2073-2082.	1.6	2
5	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Research, 2021, 31, 162-172.	1.2	6
6	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. Journal of Allergy and Clinical Immunology, 2021, 147, 1594-1601.	2.9	27
7	Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains. Journal of Geriatric Oncology, 2021, , .	1.0	0
8	Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience. Oncology, 2020, 98, 174-178.	1.9	13
9	Power calculations for the sequential parallel comparison design with continuous outcomes. Journal of Biopharmaceutical Statistics, 2020, 30, 1121-1129.	0.8	3
10	Multi-stage adaptive enrichment trial design with subgroup estimation. Journal of Biopharmaceutical Statistics, 2020, 30, 1038-1049.	0.8	5
11	Guest editorsâ€™note on the special issue innovative design and analysis of complex clinical trials. Journal of Biopharmaceutical Statistics, 2020, 30, 947-947.	0.8	0
12	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1026-1037.	0.8	11
13	Futility stopping in clinical trials, optimality and practical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1050-1059.	0.8	7
14	Continual reassessment method with regularization in phase I clinical trials. Journal of Biopharmaceutical Statistics, 2020, 30, 964-978.	0.8	0
15	Defining the learning curve for successful staging with sentinel lymph node biopsy for endometrial cancer among surgeons at an academic institution. International Journal of Gynecological Cancer, 2020, 30, 346-351.	2.5	21
16	Methods for clarifying criteria for study continuation at interim analysis. Pharmaceutical Statistics, 2020, 19, 720-732.	1.3	1
17	Permutation and Bootstrap Testing for the Sequential Parallel Comparison Design. Statistics in Biopharmaceutical Research, 2019, 11, 44-51.	0.8	6
18	Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker. Journal of Biopharmaceutical Statistics, 2019, 29, 685-695.	0.8	4

#	Article	IF	Citations
19	Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups. Journal of Biopharmaceutical Statistics, 2019, 29, 625-634.	0.8	0
20	Randomization-based analysis of covariance for inference in the sequential parallel comparison design. Journal of Biopharmaceutical Statistics, 2019, 29, 696-713.	0.8	3
21	Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.. Journal of Clinical Oncology, 2019, 37, 587-587.	1.6	0
22	Sequential parallel comparison design with binary and timeâ€toâ€event outcomes. Statistics in Medicine, 2018, 37, 1454-1466.	1.6	14
23	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. American Journal of Nephrology, 2018, 47, 275-282.	3.1	31
24	Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Nonâ€“Small-Cell LungÂCancer. Clinical Lung Cancer, 2018, 19, e481-e487.	2.6	12
25	Donor lymphocyte infusion and methotrexate for immune recovery after Tâ€cell depleted haploidentical transplantation. American Journal of Hematology, 2018, 93, 169-178.	4.1	9
26	Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. American Journal of Nephrology, 2018, 48, 21-31.	3.1	42
27	Dose-finding designs for trials of molecularly targeted agents and immunotherapies. Journal of Biopharmaceutical Statistics, 2017, 27, 477-494.	0.8	19
28	Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design. Journal of Biopharmaceutical Statistics, 2017, 27, 416-425.	0.8	2
29	Selection of the initial design for the two-stage continual reassessment method. Journal of Biopharmaceutical Statistics, 2017, 27, 495-506.	0.8	2
30	Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. American Journal of Kidney Diseases, 2017, 70, 762-769.	1.9	22
31	A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma.. Journal of Clinical Oncology, 2017, 35, TPS3095-TPS3095.	1.6	8
32	The rapid enrollment design for Phase I clinical trials. Statistics in Medicine, 2016, 35, 2516-2524.	1.6	17
33	Can sequential parallel comparison design and two-way enriched design be useful in medical device clinical trials?. Journal of Biopharmaceutical Statistics, 2016, 26, 167-177.	0.8	3
34	Practical designs for Phase I combination studies in oncology. Journal of Biopharmaceutical Statistics, 2016, 26, 150-166.	0.8	12
35	Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. Journal of Biopharmaceutical Statistics, 2016, 26, 141-149.	0.8	15
36	Two-stage design for phase II oncology trials with relaxed futility stopping. Statistics and Its Interface, 2016, 9, 93-98.	0.3	3

#	Article	IF	Citations
37	Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials. Journal of Biopharmaceutical Statistics, 2015, 25, 1206-1214.	0.8	2
38	Comment. Statistics in Biopharmaceutical Research, 2015, 7, 357-358.	0.8	0
39	Monitoring rules for toxicity in Phase II oncology trials. Clinical Investigation, 2015, 5, 373-381.	0.0	5
40	Dose finding with continuous outcome in phase I oncology trials. Pharmaceutical Statistics, 2015, 14, 102-107.	1.3	6
41	Higher order response-adaptive urn designs for clinical trials with highly successful treatments. Journal of the Royal Statistical Society Series C: Applied Statistics, 2015, 64, 175-189.	1.0	2
42	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 2129-2135.	2.0	14
43	A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. Statistical Methods in Medical Research, 2015, 24, 871-890.	1.5	31
44	Advances in Statistical Approaches to Oncology Drug Development. Therapeutic Innovation and Regulatory Science, 2014, 48, 81-89.	1.6	1
45	Dose Finding With the Sequential Parallel Comparison Design. Journal of Biopharmaceutical Statistics, 2014, 24, 1091-1101.	0.8	4
46	Dose finding when the target dose is on a plateau of a doseâ€“response curve: comparison of fully sequential designs. Pharmaceutical Statistics, 2013, 12, 309-314.	1.3	4
47	A Two-cohort Phase I Study of Weekly Oxaliplatin and Gemcitabine, Then Oxaliplatin, Gemcitabine, and Erlotinib During Radiotherapy for Unresectable Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 250-253.	1.3	6
48	Letter to the Editor. Journal of Biopharmaceutical Statistics, 2013, 23, 709-710.	0.8	0
49	When should the sequential parallel comparison design be used in clinical trials?. Clinical Investigation, 2013, 3, 823-833.	0.0	24
50	A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 1331-1337.	1.3	15
51	Twoâ€stage designs for Phase 2 doseâ€finding trials. Statistics in Medicine, 2012, 31, 2872-2881.	1.6	13
52	Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates. Journal of Statistical Planning and Inference, 2012, 142, 1899-1907.	0.6	1
53	Efficient designs for phase II oncology trials with ordinal outcome. Statistics and Its Interface, 2012, 5, 463-469.	0.3	4
54	Response-Adaptive Designs. , 2012, , 1157-1161.		0

#	Article	IF	Citations
55	Optimality, sample size, and power calculations for the sequential parallel comparison design. Statistics in Medicine, 2011, 30, 2793-2803.	1.6	52
56	A Phase I Study of Bortezomib in Combination With Standard 5-Fluorouracil and External-Beam Radiation Therapy for the Treatment of Locally Advanced or Metastatic Rectal Cancer. Clinical Colorectal Cancer, 2010, 9, 119-125.	2.3	27
57	Response-Adaptive Designs. , 2010, , 1157-1161.		0
58	An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations. Journal of Biopharmaceutical Statistics, 2009, 19, 247-255.	0.8	15
59	Comparison of Isotonic Designs for Dose-Finding. Statistics in Biopharmaceutical Research, 2009, 1, 101-107.	0.8	12
60	An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover doseâ€finding study. Statistics in Medicine, 2009, 28, 2941-2951.	1.6	18
61	Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach. Biometrics, 2009, 65, 307-315.	1.4	38
62	Efficient generation of constrained block allocation sequences. Statistics in Medicine, 2008, 27, 1421-1428.	1.6	21
63	Adaptive dose finding based on tâ€statistic for doseâ€“response trials. Statistics in Medicine, 2008, 27, 1581-1592.	1.6	24
64	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. Clinical Trials, 2008, 5, 478-485.	1.6	23
65	Cumulative cohort design for dose-finding. Journal of Statistical Planning and Inference, 2007, 137, 2316-2327.	0.6	83
66	Bivariate isotonic design for dose-finding with ordered groups. Statistics in Medicine, 2006, 25, 2018-2026.	1.6	47
67	Escalation, group andA +B designs for dose-finding trials. Statistics in Medicine, 2006, 25, 3668-3678.	1.6	68
68	Urn designs with immigration: Useful connection with continuous time stochastic processes. Journal of Statistical Planning and Inference, 2006, 136, 1836-1844.	0.6	2
69	Response-adaptive designs for continuous outcomes. Journal of Statistical Planning and Inference, 2006, 136, 1845-1852.	0.6	8
70	Dose-Finding in Oncologyâ€”Nonparametric Methods. , 2006, , 49-58.		10
71	Continuous Toxicity Monitoring in Phase II Trials in Oncology. Biometrics, 2005, 61, 540-545.	1.4	62
72	Two-Dimensional Dose Finding in Discrete Dose Space. Biometrics, 2005, 61, 217-222.	1.4	117

#	Article	IF	Citations
73	The use of the triangular test with response-adaptive treatment allocation. Statistics in Medicine, 2005, 24, 1483-1493.	1.6	11
74	Adjusting for observable selection bias in block randomized trials. Statistics in Medicine, 2005, 24, 1537-1546.	1.6	15
75	Sequential urn designs with elimination for comparingĸî‹¶3 treatments. Statistics in Medicine, 2005, 24, 1995-2009.	1.6	7
76	A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. Statistics in Medicine, 2004, 23, 1861-1870.	1.6	55
77	A play-the-winner-type urn design with reduced variability. Metrika, 2003, 58, 1-13.	0.8	114
78	Improved up-and-down designs for phase I trials. Statistics in Medicine, 2003, 22, 69-82.	1.6	116
79	Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. Statistics in Medicine, 2003, 22, 3017-3028.	1.6	207
80	A New Doseâ€Finding Design for Bivariate Outcomes. Biometrics, 2003, 59, 1001-1007.	1.4	88
81	Adaptive Tests for Ordered Categorical Data. Journal of Modern Applied Statistical Methods, 2002, 1, 269-280.	0.2	14
82	Drawbacks to Integer Scoring for Ordered Categorical Data. Biometrics, 2001, 57, 567-570.	1.4	28
83	Optimal Adaptive Designs for Binary Response Trials. Biometrics, 2001, 57, 909-913.	1.4	207
84	Adaptive Designs for Clinical Trials with Highly Successful Treatments. Drug Information Journal, 2001, 35, 1087-1093.	0.5	16
85	Convex Hull Test for Ordered Categorical Data. Biometrics, 1998, 54, 1541.	1.4	38
86	Phase I Clinical Trials. , 0, , 1-14.		0